Bio
Philipose Mulugeta, MD, is a radiologist and the director of Therapeutic Nuclear Medicine at the Mid-Atlantic Permanente Medical Group. He is board-certified in radiology and nuclear medicine and was recognized by Baltimore Magazine as a Top Doctor.
Dr. Mulugeta received his medical degree from Vanderbilt School of Medicine in Nashville, Tenn. He completed his internship at Memorial Sloan Kettering Cancer Center in New York City. He completed his residency in diagnostic radiology and fellowship in nuclear radiology at the Hospital of the University of Pennsylvania (HUP). During his fellowship, Dr. Mulugeta was a member of the HUP Response Evaluation Criteria in Solid Tumors (RECIST) Core, a methodology used to measure how well a cancer patient responds to treatments in clinical trials.
Dr. Mulugeta joined the Mid-Atlantic Permanente Medical Group in 2017. Dr. Mulugeta focuses on the care of patients with complex cancers in collaboration with physicians in endocrinology, oncology and surgical specialties.
Dr. Mulugeta’s research interests include expanding the role of radiopharmaceutical therapy, or radioactive cancer drugs that target cancer cells, for thyroid, prostate, and neuroendocrine tumors.
